Last week saw a widespread downturn among biotech stocks. Regeneron Pharmaceuticals, however, was able to move modestly higher. Why?
A surprise buyout, MannKind's sanguine PDUFA update regarding Afrezza, and three positive clinical studies, mark this week's top biotech stories.
See which companies suffered the worst clinical setbacks in the week ending April 4.
See which big biotech and pharmaceutical companies got the best clinical results for the week ending March 28.
MannKind, GlaxoSmithKline, Myriad Genetics, and Alnylam Pharmaceuticals could all make waves in the biotech sector this morning.
Celgene's Otezla isn't going to beat antiinflamatory drugs from AbbVie, Johnson & Johnson, and Amgen on efficacy, but the biotech can still find a niche for its new psoriatic arthritis drug.
High cholesterol therapies could be ready to take a gigantic leap forward with the introduction of this new class of drugs.
AbbVie is spending more than 16% of annual sales to develop new drugs that will lesson the drug maker's dependence on the rheumatoid arthritis drug Humira. Fortunately, the Chicago-based drug manufacturer has a stable of off-patent, legacy drugs that contribute sizable sales to this R&D effort.
AbbVie's (ABBV) Humira is facing new competition in psoriatic arthritis following the FDA's recent approval of Celgene's (CELG) Otezla.
See which companies scored big in the clinic.